Noteworthy Thursday Option Activity: HPQ, CRMD, GM

CorMedix Inc. (CRMD) traded 12,556 options contracts—about 1.3 million underlying shares or ~44.3% of its one‑month average daily volume (2.8M)—led by the $9 call expiring June 18, 2026 with 1,831 contracts (~183,100 shares). General Motors Co. (GM) saw 38,071 contracts—about 3.8 million underlying shares or ~44% of its one‑month ADV (8.6M)—with the $85 call expiring Jan 16, 2026 responsible for 5,577 contracts (~557,700 shares); the concentrated call flows could reflect directional positioning or hedging and may influence intraday liquidity in both names.

Analysis

Market structure: Large call flows in CRMD (1,831 Jun-18-2026 $9 calls ≈183k shares) and GM (5,577 Jan-16-2026 $85 calls ≈558k shares) are large relative to ADV (both ≈44% of one‑month ADV), meaning dealers will likely delta-hedge by buying underlying stock, mechanically supporting price in the near term and steepening call skew/IV on those strikes. Direct winners are liquidity providers and short-dated directional buyers who can ride dealer gamma; losers are passive holders if a volatility crush follows a non‑catalyst day or if flows are simply short-term speculation. Cross-asset impact is limited but expect transient USD/credit-stable flows: sizeable equity buying from hedging could modestly tighten corporate credit spreads for issuers in the auto sector and lift equities vs bonds for short windows (days–weeks).

Risk assessment: Tail risks are binary for CRMD (trial/regulatory failure → >50% drawdown) and macro-driven for GM (recession/auto demand shock → >20% EPS hit). Immediate horizon (days) is dominated by gamma-driven price moves; short-term (weeks–months) is driven by news/earnings/trial windows and IV re-pricing; long-term (quarters) depends on fundamentals (CRMD clinical progress, GM EV/product cycle). Hidden dependencies: trades may be structured (synthetic longs, collars) not pure directional bets; dealer squaring can reverse quickly. Key catalysts: CRMD trial/regulatory milestones and GM inventory/earnings cadence within next 1–12 months.

Trade implications: For CRMD, prefer capped upside (debit call spreads) sized small: buy Jun-18-2026 $9/$15 call spread sized to risk 0.5% portfolio to capture upside while limiting IV crush exposure; alternatively sell a 6–8% OTM put for premium if willing to accumulate. For GM, establish a 1.5–3% directional exposure via Jan-16-2026 $85 call (or 2% equity buy) and hedge by selling a higher strike call (call spread) to finance cost; add to position only if open interest in the $85 strike exceeds 800k underlying equivalent or 30-day IV increases >10% vs 90-day. Rotate 1–2% capital from defensives into Autos/Suppliers only if dealer-hedge flows persist for 2–4 weeks.

Contrarian angles: The market may be over-attributing directional intent to large blocks — many blocks are structured trades or hedges, so implied volatility could collapse after short-term excitement; historical parallels include biotech option frenzies pre-readout that reverse post-noise. Don’t pursue naked long calls in CRMD: IV crush or a single negative press release can halve value; use spreads or defined-risk synthetics. Unintended consequence: crowded call hedging can create short-term liquidity spikes followed by sharp reversals when dealers unwind — cap position size and set hard stop-loss (30% on options premium or 15% on equity).

Key Decisions for Investors

• Establish a capped long in CRMD: buy the Jun-18-2026 $9/$15 debit call spread sized to risk 0.5% of portfolio (max loss = premium paid). Close or roll if CRMD implied vol drops by >8 vol points or premium falls >30% from entry within 30 days.
• Take a tactical 1.5–3% exposure to GM via Jan-16-2026 $85 call spreads (buy $85, sell $100) or buy 2% equity outright; trim if GM share price falls >12% or if auto-sector new-vehicle sales momentum weakens for two consecutive months.
• If seeking income, write 6–8% OTM puts on CRMD sized to a max assignment discipline equal to 1% portfolio (target strike = ~10–15% below current spot). Only implement if willing to own the stock and set buy-to-cover if assigned or if adverse regulatory news occurs.
• Monitor flow/IV triggers for trade scaling: add up to +1% to GM position only if $85 strike open interest >800k underlying equivalent and 30-day IV > 90-day IV by >10%; de-risk immediately if flow dries for 10 trading days.
• Risk control: cap total combined options exposure to CRMD+GM at 3% portfolio; implement hard stops (30% option-premium loss, 15% equity loss) and hedge directional exposure with 1-week defensive Treasury duration increase (move +0.25–0.5 years) during high gamma unwind risk.